Literature DB >> 580348

A pharmacokinetic evaluation of free and DNA-complexed adriamycin: a preliminary study in children with malignant disease.

M Kummen, K K Lie, S O Lie.   

Abstract

The pharmacokinetics of adriamycin given as free and in DNA-complexed form was compared in six children with malignant disease. The two types of adriamycin were given to the same child at 3--4-week intervals, thereby excluding genetic variations when comparing the results. Plasma and urine were collected during and after the drug infusion, and the drug concentrations were measured by means of a sensitive fluorimetric procedure. The study shows that one obtains: 1. a much higher plasma concentration of adriamycin when it is given in the complexed form. 2. a lower urine excretion of adriamycin and fluorescent metabolites when adriamycin is administered as the DNA-complex.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 580348     DOI: 10.1111/j.1600-0773.1978.tb02192.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  4 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Clinical and pharmacologic studies with adriamycin-DNA complex in children with malignant disease.

Authors:  S O Lie; K K Lie; A Glomstein
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

4.  Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.

Authors:  A Ferrant; R Hulhoven; A Bosly; G Cornu; J L Michaux; G Sokal
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.